Ensysce Biosciences (NASDAQ:ENSC) Posts Earnings Results, Beats Estimates By $0.51 EPS

Ensysce Biosciences (NASDAQ:ENSC) released its earnings results on Monday. The company reported ($0.75) EPS for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.51, FiscalAI reports. Ensysce Biosciences had a negative return on equity of 458.65% and a negative net margin of 200.87%.The company had revenue of $1.88 million during the quarter, compared to analysts’ expectations of $0.50 million.

Ensysce Biosciences Stock Up 4.8%

Shares of ENSC opened at $0.54 on Wednesday. The business’s 50 day moving average price is $0.55 and its 200-day moving average price is $1.33. Ensysce Biosciences has a 52 week low of $0.31 and a 52 week high of $4.85. The stock has a market cap of $1.95 million, a P/E ratio of -0.13 and a beta of 1.14.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC purchased a new position in Ensysce Biosciences during the third quarter valued at $34,000. Virtu Financial LLC purchased a new stake in shares of Ensysce Biosciences in the third quarter worth $34,000. DRW Securities LLC increased its holdings in shares of Ensysce Biosciences by 42.4% during the fourth quarter. DRW Securities LLC now owns 98,481 shares of the company’s stock valued at $91,000 after acquiring an additional 29,336 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of Ensysce Biosciences by 100.4% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 149,711 shares of the company’s stock valued at $138,000 after acquiring an additional 75,000 shares in the last quarter. Institutional investors own 5.63% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ensysce Biosciences in a report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has a consensus rating of “Sell”.

Ensysce Biosciences Company Profile

Ensysce Biosciences, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel prodrug therapies aimed at improving pain management and addressing opioid misuse. Leveraging its proprietary prodrug platform, the company designs drug candidates that convert into active pharmaceuticals through specific enzymatic action, providing controlled-release profiles and built-in abuse deterrence features.

The company’s lead product candidate, ENS100, is an investigational oral prodrug of hydrocodone engineered to reduce the potential for misuse and abuse compared to immediate-release opioid formulations.